How to Ues Real World Data to Generate New Safety Information for Drugs
Post-market pharmacovigilance could be improved to collect robust data from the use of products to generate data acceptable to regulatory agencies for new claims for the safety of the products. A new ICH guidance describes various parameters to plan for which would create such robust data. Post-market use is “free” data that could help companies … Read more